Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials.
Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune- and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.
Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, Zhunan, 35053, Taiwan.|Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), Taipei, Taiwan.
Li-Tzu
LT
Wang
Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, Zhunan, 35053, Taiwan.
Chiao-Hsuan
CH
Ting
Department of Ob/Gyn, National Taiwan University Hospital & College of Medicine, National Taiwan University, Taipei, Taiwan.
Men-Luh
ML
Yen
National Institute of Cancer Research, NHRI, Tainan, Taiwan.
Ko-Jiunn
KJ
Liu
Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), Taipei, Taiwan.|Graduate Institute of Microbiology and Immunology, NDMC, Taipei, Taiwan.
Huey-Kang
HK
Sytwu
Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, Zhunan, 35053, Taiwan.|Graduate Institute of Basic Medical Sciences, China Medical College, Taichung, Taiwan.
Kenneth K
KK
Wu
Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, Zhunan, 35053, Taiwan. blyen@nhri.org.tw.
B Linju
BL
Yen
D002986:Clinical Trials as Topic; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology / Q000628:therapy*; D056747:Immunomodulation / Q000276:immunology*; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000276:immunology
Autoimmune disease; Clinical trials; Human; Immunomodulation; Inflammation; Mesenchymal stem cells; Organ transplantation and rejection; Stem cell therapy